FREDERICK, Md., Oct. 9 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that the Australian Therapeutic Goods Administration has cleared ActiPatch for sale by its distributor, Endotherapeutics Party Limited.
"We are confident that the experienced sales professionals of Endotherapeutics will successfully launch ActiPatch in the Australian market. Endotherapeutics' team has many decades of experience in the medical devices market and their people come from well known established medical devices companies," said Andrew Whelan, President of BioElectronics Corporation.
Ivan Srejber, Managing Director of Endotherapeutics Party Limited, said "We have extensive experience in launching products and establishing significant market share for previously unknown products. We are very excited about the market potential for ActiPatch in Australia and look forward to a mutually beneficial business partnership with BioElectronics Corporation."
About Endotherapeutics Party Limited:
Founded in 1998, Endotherapeutics has provided medical technologies for the health care specialist throughout Australia. Companies represented by Endotherapeutics are leaders in their specific market segments. To learn more about Endotherapeutics Party Limited please visit http://www.endotherapeutics.com.au.
BioElectronics Corporation is the maker of ActiPatch. ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.
For more information visit http://www.bioelectronicscorp.com
Safe Harbor Statement:
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.
|SOURCE BioElectronics Corporation|
Copyright©2007 PR Newswire.
All rights reserved